

Supplemental Table 3: Summary of reports

Author	Number	Phenotype	Proteinuria	eGFR (ml/min/1.73m ²)	PLA2R levels (RU/ml)	Treatment-naïve	Relapsing	Resistant	Clinical Remission*	IR	SAE
Zonazi et al.2021	60	• Treatment naïve • Relapsing • Resistant	8.4 (5.0-10.7) g/g	64 (45-85)	160 (61,244)	32	19	09	93%	100% ^α	18 events
Vink et al. 2024	26	• Treatment naïve	7.1(5.7–10)g/10 mmol	NA	176 (115,460)	26	None	None	73%	88% ^β	04 events
Current study	22	• Relapsing • Resistant	7.24 (5.86,12.25)	62 (38,87)	139 (68,895)	None	07	15	63%	100% ^μ	05 events

eGFR- estimated glomerular filtration rate, *Excluding relapse, α- 6 months, β- 3 months, μ- 12 months, IR- immunological remission, SAE- serious adverse events, PLA2R- M-type Phospholipase A2 receptor